- Pharmaceutical group Diurnal posts an operating loss of GBP3.5m for the six months to the end of December - up from GBP1.3m a year ago.

Research and development increased to GBP1.8m from GBP926,000 and administrative expenses rose to GBP1.7m frin GBP537,000.

Chief executive Martin Whitaker said: "I am pleased to announce our first set of results as a listed company. The board is grateful for the continued support of the Company's existing shareholders together with the investment made by new investors in the GBP30m fundraising and AIM IPO in December. These monies enable the company to continue to pursue its vision of becoming a world-leading endocrinology speciality pharmaceutical company.

"In the near term, it allows Diurnal to maintain the momentum behind its late stage development programmes for treatments targeting Congenital Adrenal Hyperplasia and Adrenal Insufficiency and where we anticipate market authorisation of our first product towards the end of 2017."

At 9:57am: [LON:DNL] Diurnal Group Plc share price was +0.5p at 147p

Story provided by